References

Anderson KL, O'Neill DG, Brodbelt DC Prevalence, duration and risk factors for appendicular osteoarthritis in a UK dog population under primary veterinary care. Sci Rep. 2018; 8:(1)1-12 https://doi.org/10.1038/s41598-018-23940-z

Belshaw Z, Dean R, Asher L. Could it be osteoarthritis? How dog owners and veterinary surgeons describe identifying canine osteoarthritis in a general practice setting. Prevent Vet Med. 2020; 185 https://doi.org/10.1016/j.prevetmed.2020.105198

Belshaw Z, Yeates J. Assessment of quality of life and chronic pain in dogs. Vet J. 2018; 239:59-64 https://doi.org/10.1016/j.tvjl.2018.07.010

Bockstahler B. Rehabilitation and sports medicine in companion animals, 1st edn. Babenhausen, Germany: VBS GmbH; 2019

Burian M, Geisslinger G. COX-dependent mechanisms involved in the antinociceptive action of NSAIDs at central and peripheral sites. Pharmacol Therap Pergamon. 2005; 107:(2)139-154 https://doi.org/10.1016/j.pharmthera.2005.02.004

Dimitroulas T, Duarte RV, Behura A, Kitas GD, Raphael JH. Neuropathic pain in osteoarthritis: a review of pathophysiological mechanisms and implications for treatment. Semin Arthritis Rheum. 2014; 44:(2)145-154 https://doi.org/10.1016/j.semarthrit.2014.05.011

Epstein M, Rodan I, Griffenhagen G 2015 AAHA/AAFP pain management guidelines for dogs and cats. J Amer Anim Hosp Assoc. 2015; 51:(2)67-84 https://doi.org/10.5326/JAAHA-MS-7331

Fast R, Schütt T, Toft N An observational study with long-term follow-up of canine cognitive dysfunction: clinical characteristics, survival, and risk factors. J Vet Intern Med. 2013; 27:(4)822-829 https://doi.org/10.1111/jvim.12109

Fox SM. Multimodal management of canine osteoarthritis. Multimodal Manag Canine Osteoarthr. 2016; https://doi.org/10.1201/9781315368443

Grubb T. Chronic neuropathic pain in veterinary patients. Topics Companion Anim Med. 2010; 25:(1)45-52 https://doi.org/10.1053/j.tcam.2009.10.007

Paracetamol for long term use. 2020. https://www.zeropainphilosophy.com/post/paracetamol-for-long-term-use (accessed 10 May 2021)

Hielm-Bjorkman A. Recognition and Assessment of Chronic Pain in Dogs, 1st edn. In: Egger CM, Love L, Doherty T (eds). Hoboken (NJ): John Wiley and Sons; 2014

Hunt J, White K. Pain management in small animal practice, 1st edn. In: Self I (ed). Gloucester: BSAVA; 2019

Innes JF, Clayton J, Lascelles BDX. Review of the safety and efficacy of long-term NSAID use in the treatment of canine osteoarthritis. Vet Rec. 2010; 166:(8)226-230 https://doi.org/10.1136/vr.c97

Kukanich B, Papich MG. Pharmacokinetics of tramadol and the metabolite O-desmethyltramadol in dogs. J Vet Pharmacol Ther. 2004; 27:(4)239-246 https://doi.org/10.1111/j.1365-2885.2004.00578.x

KuKanich B, Cohen RL. Pharmacokinetics of oral gabapentin in greyhound dogs. Vet Journal. 2011; 187:(1)133-135 https://doi.org/10.1016/j.tvjl.2009.09.022

Kukanich B, Bidgood T, Knesl O. Clinical pharmacology of nonsteroidal anti-inflammatory drugs in dogs. Vet Anaesthesia Analgesia. 2012; 39:(1)69-90 https://doi.org/10.1111/j.1467-2995.2011.00675.x

KuKanich B. Outpatient oral analgesics in dogs and cats beyond nonsteroidal antiinflammatory drugs. an evidence-based approach. Vet Clin North Amer: Small Anim Pract. 2013; 43:(5)1109-1125 https://doi.org/10.1016/j.cvsm.2013.04.007

Lascelles BDX, Gaynor JS, Smith ES Amantadine in a multimodal analgesic regimen for alleviation of refractory osteoarthritis pain in dogs. J Vet Inter Med. 2008; 22:(1)53-59 https://doi.org/10.1111/j.1939-1676.2007.0014.x

Lascelles BDX, Knazovicky D, Case B A canine-specific anti-nerve growth factor antibody alleviates pain and improves mobility and function in dogs with degenerative joint disease-associated pain. BMC Vet Res. 2015; 11:(1)1-12 https://doi.org/10.1186/s12917-015-0413-x

Lawson A, Walton B. Monitoring side effects of long-term NSAID use in dogs with chronic osteoarthritis. In Pract. 2019; 41:(4)148-154 https://doi.org/10.1136/inp.l1506

Mills DS, Demontigny-Bédard I, Gruen M Pain and problem behavior in cats and dogs. Animals. 2020; 10:(2) https://doi.org/10.3390/ani10020318

Muller C, Gines JA, Conzemius M Evaluation of the effect of signalment and owner-reported impairment level on accelerometer-measured changes in activity in osteoarthritic dogs receiving a non-steroidal anti-inflammatory. Vet J. 2018; 242:48-52 https://doi.org/10.1016/j.tvjl.2018.10.005

Pozzi A, Muir WW, Traverso F. Prevention of central sensitisation and pain by N-methyl-D-aspartate receptor antagonists. J Amer Vet Med Assoc. 2006; 228:(1)53-60 https://doi.org/10.2460/javma.228.1.53

Preston T, Wills AP. A single hydrotherapy session increases range of motion and stride length in Labrador retrievers diagnosed with elbow dysplasia. Vet J. 2018; 234:105-110 https://doi.org/10.1016/j.tvjl.2018.02.013

Rausch-Derra LC, Huebner M, Rhodes L. Evaluation of the safety of long-term, daily oral administration of grapiprant, a novel drug for treatment of osteoarthritic pain and inflammation, in healthy dogs. Amer J Vet Res. 2015; 76:(10)853-859 https://doi.org/10.2460/ajvr.76.10.853

Rausch-Derra L, Huebner M, Wofford J, Rhodes L. A prospective, randomized, masked, placebo-controlled multisite clinical study of grapiprant, an EP4 prostaglandin receptor antagonist (PRA), in dogs with osteoarthritis. J Vet Intern Med. 2016; 30:(3)756-763 https://doi.org/10.1111/jvim.13948

Rossmeisl JH, Moore SA. Article 12 1 Citation: Moore SA (2016) Managing Neuropathic Pain in Dogs. Front Vet Sci. 2016; 3 https://doi.org/10.3389/fvets.2016.00012

Salazar V, Dewey CW, Schwark W Pharmacokinetics of single-dose oral pregabalin administration in normal dogs. Vet Anaesthesia Analgesia. 2009; 36:(6)574-580 https://doi.org/10.1111/j.1467-2995.2009.00486.x

Schneider BM, Dodman NH, Maranda L. Use of memantine in treatment of canine compulsive disorders. J Vet Behav Clin Appl Res. 2009; 4:(3)118-126 https://doi.org/10.1016/j.jveb.2008.10.008

Self I, Grubb T. Pain management in small animal practice, 1st edn. In: Ian S (ed). Gloucester, UK: BSAVA; 2019

Smith GK, Paster ER, Powers MY Lifelong diet restriction and radiographic evidence of osteoarthritis of the hip joint in dogs. J Amer Vet Med Assoc. 2006; 229:(5)690-693 https://doi.org/10.2460/javma.229.5.690

The Royal College of Veterinary Surgeons. Controlled drugs guidance. 2017. https://www.rcvs.org.uk/news-and-views/publications/controlled-drugs-guidance/ (Accessed 11 May 2021)

Walton MB, Cowderoy E, Lascelles D Evaluation of construct and criterion validity for the ‘Liverpool Osteoarthritis in Dogs’ (LOAD) clinical metrology instrument and comparison to two other instruments. PLoS ONE. 2013; 8:(3) https://doi.org/10.1371/journal.pone.0058125

Woolf CJ. Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med. 2004; 140:(6) https://doi.org/10.7326/0003-4819-140-8-200404200-00010

Understanding the pharmaceutical approach to pain management in canine osteoarthritis

02 June 2021
14 mins read
Volume 26 · Issue 6

Abstract

Canine osteoarthritis was recently reclassified as a welfare concern by the Veterinary Companion Animal Surveillance System (VetCompass), an initiative run by the Royal College of Veterinary Surgeons, focused on improving companion animal health. This condition is a common cause for consultation in first opinion practice, with an estimated 35% of the canine population being affected. Chronic pain is complex and a multimodal approach is best for management, which includes pharmaceuticals employed in a methodical manner. This article provides an overview of the types of pain associated with canine osteoarthritis, as well as how to recognise them. Making reference to hypothetical cases, the appropriate pharmaceutical management is described. Further management strategies, as part of a multimodal approach, are summarised to ensure best practice.

Canine osteoarthritis, estimated to affect 35% of the canine population (Muller et al, 2018), is a leading cause of chronic pain, which is often more appropriately termed maladaptive pain. While chronic pain is likely to be of long duration, that is not likely to be its sole feature. Chronic pain is a complex pathophysiological experience, differing from acute pain, that affects the whole body through inducing a sustained catabolic state, as well as having a negative impact on cognitive and emotional health long-term (Woolf, 2004; Self and Grubb, 2019).

Acute nociceptive pain has physiological benefit, as it signals potential or actual tissue damage caused by stimuli such as heat, cold, pressure or chemicals. It protects through causing appropriate action to be taken by the dog to avoid harm and encourages behaviours that support healing. Although this pain is adaptive, it still needs addressing with a comprehensive, prompt, targeted pain management approach.

Register now to continue reading

Thank you for visiting UK-VET Companion Animal and reading some of our peer-reviewed content for veterinary professionals. To continue reading this article, please register today.